D-1456-2019 Class II Ongoing

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-1456-2019 was initiated by Teva Pharmaceuticals USA on Jun 6, 2019 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is ongoing. Affected quantity: 2,943,000 tablets.

Recall details

Product Type
Drugs
Report Date
Jul 17, 2019
Initiation Date
Jun 6, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,943,000 tablets

Product description

LOSARTAN POTASSIUM 100 mg TABLET BULK 90 count bottles, NDC 00591-3747-00

Reason for recall

CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.

Distribution pattern

Nationwide by 4 major distributors.

Code information

Arrow Malta (Teva) Bulk Product Lot # 1163892A, exp. date 01/2020 1163893A, exp. date 01/2020 1163894A, exp. date 01/2020 1163895A, exp. date 01/2020 Golden State Medical Finished Product Lot # GS017042, exp. date 01/2020 GS017043, exp. date 01/2020 GS017044, exp. date 01/2020 GS017541, exp. date 01/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1456-2019
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1456-2019. Report a data issue: hello@regdatalab.com.